AtheroGenics , Inc. Information

AtheroGenics is a publicly traded, emerging pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceutical products that address critical unmet needs in the treatment of chronic inflammatory diseases, including diabetes and atherosclerosis. The Company's lead compound, AGI-1067, is a novel orally available anti-oxidant with anti-inflammatory properties that was discovered by AtheroGenics scientists. AtheroGenics is studying AGI-1067 in a Phase III clinical trial called ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation Study) to assess the ability of AGI-1067 to control blood sugar levels in patients with diabetes. Patient enrollment in ANDES was completed in December 2007. A pre-planned interim analysis to evaluate the efficacy and safety of AGI-1067 after three months of dosing will be conducted in the second quarter of 2008. The Company expects to release final data on the full six months of dosing during the second half of 2008. AtheroGenics was incorporated in Georgia in 1993 and is based in Alpharetta, Georgia. The Company currently has 70 employees, with a senior management team comprised of executives from leading pharmaceutical companies and academic institutions.